Man Collapses Behind Trump During Obesity Drug Press Conference (Video)

A startling scene unfolded inside the Oval Office Thursday when a man suddenly collapsed just feet behind President Donald J. Trump during a live press conference unveiling a historic deal to slash the cost of obesity medications for millions of Americans.

The incident occurred just moments after Trump began outlining his plan to expand Medicare coverage and dramatically lower prices on the in-demand weight-loss drugs Zepbound and Wegovy — a move widely seen as a political and healthcare victory heading into the 2026 midterms.

As the president addressed the nation, a man believed to be a pharmaceutical representative with one of the attending companies suddenly lost consciousness and dropped to the floor, prompting gasps from the room and immediate action from officials.

In a surreal moment caught on closed press feeds, Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz, known to millions of Americans from his years on television, was seen swiftly catching the man’s head and easing him to the floor before calling for medical backup.

White House staff promptly cleared reporters from the room. Secret Service moved in, and the White House Medical Unit was on the scene within seconds.

Press Secretary Karoline Leavitt issued a statement shortly after:

“During the Most Favored Nations announcement, a representative from one of the participating companies fainted. The White House Medical Unit responded immediately. We’re relieved to report the gentleman is okay and recovering. President Trump will resume the event shortly.”

Roughly an hour after the incident, Trump returned to the podium and resumed the press conference with his characteristic determination.

“He got a little lightheaded — happens to the best of us. But he’s alright now, folks. We’re going to keep moving forward,” Trump said, earning applause from attendees.

The identity of the man was not officially released, though the White House clarified he was not a member of the administration but a guest of either Eli Lilly or Novo Nordisk, the two pharmaceutical giants at the center of the deal. Despite early reports incorrectly naming a Novo Nordisk executive, the company later confirmed that only CEO Mike Doustdar and EVP Dave Moore were present.

The health scare temporarily overshadowed what may be one of the biggest healthcare wins of Trump’s second term. Under the agreement brokered by the Trump administration, Medicare will now cover obesity treatments such as Zepbound and Wegovy — drugs that can cost Americans up to $500 a month without insurance.

Additionally, pill versions of the drugs, currently pending FDA approval, may be available for as low as $149/month by early 2026.

“We’re making these life-saving medications affordable — finally. No more games, no more Big Pharma markups. We’re taking action,” President Trump declared.

Secretary of Health and Human Services Robert F. Kennedy Jr., who joined the president at the announcement, called the move “a game-changer” and noted the impact it would have on lower-income families.

“Obesity is a disease of poverty,” Kennedy said. “President Trump is delivering relief where others have only made excuses.”

The administration also introduced TrumpRx, a new program offering reduced drug costs to uninsured Americans. Starting immediately, GLP-1 drugs will be available through the program for $350, with plans to drop the price to $245 over two years.

Obesity continues to be a public health crisis in the U.S., impacting more than 42% of adults, according to the CDC. These weight-loss medications — originally developed for diabetes — have become a sensation for their ability to help users shed pounds safely and quickly.

But until now, most insurance plans refused to cover them for non-diabetic patients. That’s about to change under Trump’s directive, a move Republicans say restores affordability and choice to American families.

“This is about freedom — freedom to live a healthier life without being buried under a pharmacy bill,” said Heidi Overton, director of the White House Domestic Policy Council.

Despite the medical scare, President Trump remained undeterred in his mission to drive down prescription drug costs — an issue he has prioritized since returning to office. The Oval Office press conference marked a pivotal moment in the administration’s health policy agenda.

“We’re putting the American patient first,” Trump said. “And we’re just getting started.”